BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Re-appointment of Ms. Akshita Ostwal as Independent Director of the company w.e.f. September 05, 2026 subject to shareholders approval in ensuing AGM.
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Balaxi Pharmaceuticals reported strong FY2026 standalone net profit of Rs 514.69 lakhs (up 43% from Rs 360.13 lakhs in FY2025) on revenue of Rs 8,085.11 lakhs. Consolidated net profit was Rs 141.69 lakhs on revenue of Rs 27,017.35 lakhs. The Board recommended re-appointing Ms. Akshita Ostwal as Independent Director for a second 5-year term from September 5, 2026, pending shareholder approval at the August 24, 2026 AGM. Key highlight: the company's first pharmaceutical formulation plant at Jadcherla, Hyderabad received its Manufacturing Licence on May 23, 2026, enabling commercialization of Paracetamol and Piroxicam products. The company is pursuing WHO-GMP certification and seeking permissions for 40 additional products. Statutory auditors issued unmodified opinions on both standalone and consolidated financials.
Positive signals include strong standalone profit growth and a new manufacturing licence that opens revenue streams. The director re-appointment is routine governance. Shareholders should note the upcoming AGM for voting on the independent director re-appointment.